HI
CLDX icon

HBK Investments’s Celldex Therapeutics CLDX Stock Holding History

HBK Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,191
Closed -$316K – 938
2014
Q1 		$316K Buy
+1,191
New +$456K 0.01% 774
2013
Q3 		– Sell
-7,467
Closed -$1.75M – 875
2013
Q2 		$1.75M Buy
+7,467
New +$1.47M 0.03% 293

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HBK Investments's CLDX Position: Q2 2014 in Review

HBK Investments sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 1,191 shares — an estimated $316K sold.

HBK Investments first reported a position in CLDX in Q2 2013 and held it in 2 quarters. The position peaked at $1.75M in Q2 2013. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • HBK Investments reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • HBK Investments sold 1,191 Celldex Therapeutics shares in Q2 2014, an estimated $316K.
  • HBK Investments first reported a position in Celldex Therapeutics in Q2 2013 and held it in 2 quarters.
  • HBK Investments's Celldex Therapeutics position peaked at $1.75M in Q2 2013.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on HBK Investments's 13F filing for Q2 2014, filed 14 Aug 2014.